Drugs / NmVac4-A/C/Y/W-135-DT™
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01482052 Comparator | Nov 2011 → Jan 2013 | meningococcal meningitis | JN-International Medical Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NmVac4-A/C/Y/W-135-DT | “NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid.” NCT01482052 ↗ |
| Modality | Vaccine | “NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine” NCT01482052 ↗ |
| Route | Intramuscular | “Single intramuscular 0.5 mL dose” NCT01482052 ↗ |